Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis

World J Gastroenterol. 2011 Jan 28;17(4):459-69. doi: 10.3748/wjg.v17.i4.459.


Aim: To assess the anti-inflammatory effect of the probiotic Bifidobacterium lactis (B. lactis) in an adoptive transfer model of colitis.

Methods: Donor and recipient mice received either B. lactis or bacterial culture medium as control (deMan Rogosa Sharpe) in drinking water for one week prior to transfer of a mix of naive and regulatory T cells until sacrifice.

Results: All recipient mice developed signs of colonic inflammation, but a significant reduction of weight loss was observed in B. lactis-fed recipient mice compared to control mice. Moreover, a trend toward a diminution of mucosal thickness and attenuated epithelial damage was revealed. Colonic expression of pro-inflammatory and T cell markers was significantly reduced in B. lactis-fed recipient mice compared to controls. Concomitantly, forkhead box protein 3, a marker of regulatory T cells, was significantly up-regulated by B. lactis.

Conclusion: Daily oral administration of B. lactis was able to reduce inflammatory and T cells mediators and to promote regulatory T cells specific markers in a mouse model of colitis.

Keywords: Adoptive transfer model; Bifidobacterium; Colitis; Inflammation; Mice; Probiotics; Regulatory T cells.

MeSH terms

  • Adoptive Transfer
  • Animals
  • Bifidobacterium / immunology*
  • Biomarkers / metabolism
  • Body Weight
  • Colitis / immunology*
  • Colitis / microbiology*
  • Colitis / pathology*
  • Disease Models, Animal
  • Feces / microbiology
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / immunology
  • Inflammation / microbiology*
  • Mice
  • Mice, Inbred C57BL
  • Probiotics / administration & dosage
  • Probiotics / therapeutic use*
  • T-Lymphocytes / immunology


  • Biomarkers